title: [Low-dose methotrexate combined with vinorelbine for inoperable desmoid tumor: efficacy and the prognostic factors].
abstract: OBJECTIVE
  To characterize the clinical features of desmoid tumor, assess the efficacy of conservative chemotherapy for inoperable desmoid tumor and analyze the prognostic factors.
  
  
  METHODS
  From August 2009 to December 2013, 52 patients with inoperable desmoid tumor were treated in our department and received chemotherapy with vinorelbine combined with low-dose methotrexate. The clinical data of the patients were analyzed retrospectively.
  
  
  RESULTS
  The patients studied included 22 male and 30 female patients with the age of disease onset ranging from 2 to 46 years (mean 18.7 years). The lesions occurred most frequently in the lower limbs (36.5%, 19/52) and the tumor size ranged from 2.7 to 37 cm (mean 9.5 cm). The patients were followed up for a median of 29 months (7 to 64 months). The chemotherapy lasted for 4 to 30 months (median 12 months). After completion of the chemotherapy, 1 patient had a complete response (CR), 18 showed partial responses (PR), 27 cases had stable disease (SD), and 6 had progressive disease (PD), with an overall response rate (ORR) of 88.5%. The progression-free survival (PFS) time of the patients ranged from 4 to 63 months (median 26.5 months) with a 2-year PFS rate of 76.7% and 5-year PFS rate of 41.9%. A longer chemotherapy duration (over 12 months) was associated with a more favorable prognosis. No significant differences in PFS were found between the patients stratified by gender, age of disease onset, age when receiving chemotherapy, tumor site, or tumor size.
  
  
  CONCLUSIONS
  For recurrent, inoperable and progressive desmoid tumor, long enough cycles of vinorelbine combined with low-dose methotrexate can be an effective and safe option for tumor control.
authors.affiliation: Key laboratory of Carcinogenesis and Translational Research of Ministry of Education, Department of Bone and Soft tissue tumors, Peking University Cancer Hospital and Beijing Institute for Cancer Research, Beijing 100142, China.E-mail: zhengfufan@126.com.
authors.forename: Zhengfu
authors.initials: Z
authors.lastname: Fan
authors.forename: Shu
authors.initials: S
authors.lastname: Li
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Fang
authors.forename: Jiayong
authors.initials: J
authors.lastname: Liu
authors.forename: Chujie
authors.initials: C
authors.lastname: Bai
authors.forename: Ruifeng
authors.initials: R
authors.lastname: Xue
authors.forename: Lu
authors.initials: L
authors.lastname: Zhang
authors.forename: Tian
authors.initials: T
authors.lastname: Gao
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D018222:Desmoid Tumors / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine; D055815:Young Adult
chemical_list: D014747:Vinblastine; D000077235:Vinorelbine; D008727:Methotrexate